Published 2022 | Version v1
Publication

Predictors of Serious Adverse Events and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis treated with Obeticholic Acid

Description

Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed at better defining the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy.

Additional details

Created:
February 14, 2024
Modified:
February 14, 2024